| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
INSM Stock Overview
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.
Insmed Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.40 |
| 52 Week High | US$34.44 |
| 52 Week Low | US$16.41 |
| Beta | 1.91 |
| 1 Month Change | 18.46% |
| 3 Month Change | 27.44% |
| 1 Year Change | 19.70% |
| 3 Year Change | 62.32% |
| 5 Year Change | 128.72% |
| Change since IPO | -83.39% |
Recent News & Updates
Insmed rises 16% on better-than-expected Q2 result
Insmed (NASDAQ:INSM) is trading 16% higher after the company reported Q2 result that beat estimates, helped by higher sales of lung disease treatment, Arikayce. Arikayce net sales were $47.2M in the U.S., $15.8M in Japan, and $2.2M in Europe and rest of world. Q2 GAAP EPS of -$0.80 beats by $0.09, while revenue rose 43.6% to $65.2M, and beats by $6.28M. The company continues to expect full-year global revenues for Arikayce to increase at least 30% year over year from 2021 and expects that its cash on hand will support its ongoing business into 2024. Cost of product revenues rose 52% Y/Y to $16.4M.
Shareholder Returns
| INSM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.0% | 1.4% | 3.6% |
| 1Y | 19.7% | -19.6% | -9.6% |
Return vs Industry: INSM exceeded the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: INSM exceeded the US Market which returned -10.2% over the past year.
Price Volatility
| INSM volatility | |
|---|---|
| INSM Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 12.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: INSM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: INSM's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 613 | Will Lewis | https://www.insmed.com |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.
Insmed Incorporated Fundamentals Summary
| INSM fundamental statistics | |
|---|---|
| Market Cap | US$3.27b |
| Earnings (TTM) | -US$415.96m |
| Revenue (TTM) | US$221.21m |
14.9x
P/S Ratio-7.9x
P/E RatioIs INSM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INSM income statement (TTM) | |
|---|---|
| Revenue | US$221.21m |
| Cost of Revenue | US$52.06m |
| Gross Profit | US$169.15m |
| Other Expenses | US$585.11m |
| Earnings | -US$415.96m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.47 |
| Gross Margin | 76.47% |
| Net Profit Margin | -188.04% |
| Debt/Equity Ratio | 1,772.1% |
How did INSM perform over the long term?
See historical performance and comparison